Hepatitis C – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 7 PAGES: 280

More Info
									                           Hepatitis C – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1730IDB
                                                                                           Publication Date: February 2012




Hepatitis C – Pipeline Review, H1 2012                                                     GMDHC1730IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Hepatitis C – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 9
    List of Figures .............................................................................................................................................................................. 13
Introduction....................................................................................................................................................................................... 14
    Global Markets Direct Report Coverage ...................................................................................................................................... 14
Hepatitis C Overview ........................................................................................................................................................................ 15
Therapeutics Development............................................................................................................................................................... 16
    An Overview of Pipeline Products for Hepatitis C ........................................................................................................................ 16
Hepatitis C Therapeutics under Development by Companies .......................................................................................................... 18
Hepatitis C Therapeutics under Investigation by Universities/Institutes ........................................................................................... 27
Late Stage Products ......................................................................................................................................................................... 31
    Comparative Analysis .................................................................................................................................................................. 31
Mid Clinical Stage Products.............................................................................................................................................................. 32
    Comparative Analysis .................................................................................................................................................................. 32
Early Clinical Stage Products ........................................................................................................................................................... 33
    Comparative Analysis .................................................................................................................................................................. 33
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 34
    Comparative Analysis .................................................................................................................................................................. 34
Hepatitis C Therapeutics – Products under Development by Companies ........................................................................................ 35
Hepatitis C Therapeutics – Products under Investigation by Universities/Institutes ......................................................................... 53
Companies Involved in Hepatitis C Therapeutics Development ....................................................................................................... 57
    Bristol-Myers Squibb Company ................................................................................................................................................... 57
    Boehringer Ingelheim GmbH ....................................................................................................................................................... 58
    F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 59
    Abbott Laboratories ..................................................................................................................................................................... 60
    United Therapeutics Corporation ................................................................................................................................................. 61
    Medgenics Inc. ............................................................................................................................................................................ 62
    Valeant Pharmaceuticals International ........................................................................................................................................ 63
    GlaxoSmithKline plc .................................................................................................................................................................... 64
    Tekmira Pharmaceuticals Corp. .................................................................................................................................................. 65
    Idenix Pharmaceuticals, Inc. ........................................................................................................................................................ 66
    Gilead Sciences, Inc. ................................................................................................................................................................... 67
    Merck & Co., Inc. ......................................................................................................................................................................... 68
    Lentigen Corporation ................................................................................................................................................................... 69
    ChemDiv, Inc. .............................................................................................................................................................................. 70
    Biotron Limited............................................................................................................................................................................. 71
    Novartis AG ................................................................................................................................................................................. 72
    Samyang Corporation.................................................................................................................................................................. 73
    Achillion Pharmaceuticals, Inc. .................................................................................................................................................... 74
    Cubist Pharmaceuticals, Inc. ....................................................................................................................................................... 75
    Dong-A Pharmaceutical Co., Ltd. ................................................................................................................................................ 76
    Hanmi Pharmaceutical Co Ltd ..................................................................................................................................................... 77



Hepatitis C – Pipeline Review, H1 2012                                                                                                     GMDHC1730IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Hepatitis C – Pipeline Review, H1 2012




    InterMune, Inc.............................................................................................................................................................................. 78
    Japan Tobacco Inc. ..................................................................................................................................................................... 79
    Meiji Holdings Co., Ltd................................................................................................................................................................. 80
    Ono Pharmaceutical Co., Ltd....................................................................................................................................................... 81
    Pfizer Inc...................................................................................................................................................................................... 82
    SuperGen, Inc. ............................................................................................................................................................................ 83
    Toyama Chemical Co. Ltd ........................................................................................................................................................... 84
    Vertex Pharmaceuticals Incorporated.......................................................................................................................................... 85
    Genmab A/S ................................................................................................................................................................................ 86
    Progenics Pharmaceuticals, Inc. ................................................................................................................................................. 87
    Avexa Limited .............................................................................................................................................................................. 88
    Santaris Pharma A/S ................................................................................................................................................................... 89
    Tacere Therapeutics, Inc. ............................................................................................................................................................ 90
    Crucell N.V. ................................................................................................................................................................................. 91
    Inhibitex, Inc. ............................................................................................................................................................................... 92
    Hemispherx Biopharma, Inc. ....................................................................................................................................................... 93
    Can-Fite BioPharma Ltd. ............................................................................................................................................................. 94
    Intercell AG .................................................................................................................................................................................. 95
    Medivir AB ................................................................................................................................................................................... 96
    Biota Holdings Limited ................................................................................................................................................................. 97
    Biovitrum AB ................................................................................................................................................................................ 98
    Novelos Therapeutics, Inc. .......................................................................................................................................................... 99
    Pacgen Biopharmaceuticals Corporation .................................................................................................................................. 100
    Peregrine Pharmaceuticals, Inc. ................................................................................................................................................ 101
    Pharmasset, Inc......................................................................................................................................................................... 102
    Amarillo Biosciences, Inc........................................................................................................................................................... 103
    Anadys Pharmaceuticals, Inc .................................................................................................................................................... 104
    Flamel Technologies S.A........................................................................................................................................................... 105
    Dynavax Technologies Corporation........................................................................................................................................... 106
    Transgene SA............................................................................................................................................................................ 107
    Lipoxen PLC .............................................................................................................................................................................. 108
    Bukwang Pharmaceutical Co., Ltd............................................................................................................................................. 109
    Miraca Holdings Inc. .................................................................................................................................................................. 110
    Hanall Pharmaceutical Co., Ltd. ................................................................................................................................................ 111
    Samaritan Pharmaceuticals, Inc. ............................................................................................................................................... 112
    LTT Bio-Pharma Co., Ltd........................................................................................................................................................... 113
    Summit Corporation plc ............................................................................................................................................................. 114
    Phynova Group Ltd.................................................................................................................................................................... 115
    Tripep AB................................................................................................................................................................................... 116
    Digna Biotech, S.L. .................................................................................................................................................................... 117
    Debiopharm Group .................................................................................................................................................................... 118
    StemCells, Inc. .......................................................................................................................................................................... 119
    Maywufa Company Limited ....................................................................................................................................................... 120
    SCYNEXIS, Inc.......................................................................................................................................................................... 121


Hepatitis C – Pipeline Review, H1 2012                                                                                                      GMDHC1730IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(3)
Hepatitis C – Pipeline Review, H1 2012




    Nutri Pharma ASA ..................................................................................................................................................................... 122
    Biolex Therapeutics, Inc. ........................................................................................................................................................... 123
    Cytheris SA................................................................................................................................................................................ 124
    Altor BioScience Corporation..................................................................................................................................................... 125
    Eiger BioPharmaceuticals, Inc. .................................................................................................................................................. 126
    AiCuris GmbH & Co. KG ........................................................................................................................................................... 127
    Okairos ...................................................................................................................................................................................... 128
    PTC Therapeutics, Inc. .............................................................................................................................................................. 129
    Conatus Pharmaceuticals Inc. ................................................................................................................................................... 130
    Rottapharm SpA ........................................................................................................................................................................ 131
    Presidio Pharmaceuticals, Inc. .................................................................................................................................................. 132
    Romark Laboratories, L.C. ........................................................................................................................................................ 133
    Avila Therapeutics, Inc. ............................................................................................................................................................. 134
    Phage Biotechnology Corporation ............................................................................................................................................. 135
    Intarcia Therapeutics, Inc. ......................................................................................................................................................... 136
    REPLICor Inc............................................................................................................................................................................. 137
    Biotica Technology Ltd .............................................................................................................................................................. 138
    Sinovac Biotech Ltd. .................................................................................................................................................................. 139
    Virobay Inc................................................................................................................................................................................. 140
    Implicit Bioscience Limited ........................................................................................................................................................ 141
    Oncolys BioPharma Inc. ............................................................................................................................................................ 142
    Globeimmune, Inc. .................................................................................................................................................................... 143
    Immunocore Limited. ................................................................................................................................................................. 144
    Enanta Pharmaceuticals, Inc. .................................................................................................................................................... 145
    Canopus BioPharma Incorporated ............................................................................................................................................ 146
    Epiphany Biosciences, Inc. ........................................................................................................................................................ 147
    Beckpharma Limited .................................................................................................................................................................. 148
    CureTech Ltd. ............................................................................................................................................................................ 149
    TaiGen Biotechnology Co., Ltd. ................................................................................................................................................. 150
    PharmaEssentia Corporation..................................................................................................................................................... 151
    NasVax Ltd. ............................................................................................................................................................................... 152
    Regulus Therapeutics Inc. ......................................................................................................................................................... 153
    Kemin Industries, Inc. ................................................................................................................................................................ 154
    Vakzine Projekt Management GmbH ........................................................................................................................................ 155
    C-Pharma, Inc. .......................................................................................................................................................................... 156
    Therapure Biopharma Inc. ......................................................................................................................................................... 157
    VectorLogics, Inc. ...................................................................................................................................................................... 158
    iTherX Pharmaceuticals Inc. ...................................................................................................................................................... 159
    Tibotec Therapeutics ................................................................................................................................................................. 160
Hepatitis C – Therapeutics Assessment ......................................................................................................................................... 161
    Assessment by Monotherapy Products ..................................................................................................................................... 161
    Assessment by Combination Products ...................................................................................................................................... 162
    Assessment by Route of Administration .................................................................................................................................... 163
    Assessment by Molecule Type .................................................................................................................................................. 166


Hepatitis C – Pipeline Review, H1 2012                                                                                                     GMDHC1730IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(4)
Hepatitis C – Pipeline Review, H1 2012




Drug Profiles................................................................................................................................................................................... 169
    Vaniprevir - Drug Profile ............................................................................................................................................................ 169
        Product Description............................................................................................................................................................... 169
        Mechanism of Action ............................................................................................................................................................. 169
        R&D Progress ....................................................................................................................................................................... 169
    Incivek - Drug Profile ................................................................................................................................................................. 170
        Product Description............................................................................................................................................................... 170
        Mechanism of Action ............................................................................................................................................................. 170
        R&D Progress ....................................................................................................................................................................... 170
    Debio 025 + Peginterferon Alpha-2a + Ribavirin - Drug Profile ................................................................................................. 172
        Product Description............................................................................................................................................................... 172
        Mechanism of Action ............................................................................................................................................................. 172
        R&D Progress ....................................................................................................................................................................... 172
    Paclitaxel - Drug Profile ............................................................................................................................................................. 174
        Product Description............................................................................................................................................................... 174
        Mechanism of Action ............................................................................................................................................................. 174
        R&D Progress ....................................................................................................................................................................... 174
    BI 201335 - Drug Profile ............................................................................................................................................................ 175
        Product Description............................................................................................................................................................... 175
        Mechanism of Action ............................................................................................................................................................. 175
        R&D Progress ....................................................................................................................................................................... 175
    Alferon N Injection - Drug Profile ............................................................................................................................................... 176
        Product Description............................................................................................................................................................... 176
        Mechanism of Action ............................................................................................................................................................. 176
        R&D Progress ....................................................................................................................................................................... 176
    Revolade - Drug Profile ............................................................................................................................................................. 177
        Product Description............................................................................................................................................................... 177
        Mechanism of Action ............................................................................................................................................................. 177
        R&D Progress ....................................................................................................................................................................... 177
    NOV-205 - Drug Profile ............................................................................................................................................................. 180
        Product Description......
								
To top